Abstract
Many cancers demonstrate aberrant splicing patterns that contribute to their development and progression. Recently, recurrent somatic mutations of genes encoding core subunits of the spliceosome have been identified in several different cancer types. These mutations are most common in hematologic malignancies like the myelodysplastic syndromes (MDS), acute myeloid leukemia, and chronic lymphocytic leukemia, but also in occur in several solid tumors at lower frequency. The most frequent mutations occur in SF3B1, U2AF1, SRSF2, and ZRSR2 and are largely exclusive of each other. Mutations in SF3B1, U2AF1, and SRSF2 acquire heterozygous missense mutations in specific codons, resembling oncogenes. ZRSR2 mutations include clear loss-of-function variants, a pattern more common to tumor suppressor genes. These splicing factors are associated with distinct clinical phenotypes and patterns of mutation in different malignancies. Mutations have both diagnostic and prognostic relevance. Splicing factor mutations appear to affect only a minority of transcripts which show little overlap by mutation type. How differences in splicing caused by somatic mutations of spliceosome subunits lead to oncogenesis is not clear and may involve different targets in each disease type. However, cells with mutated splicing machinery may be particularly vulnerable to further disruption of the spliceosome suggesting a novel strategy for the targeted therapy of cancers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
La Cognata V, Iemmolo R, D’Agata V et al (2014) Increasing the coding potential of genomes through alternative splicing: the case of PARK2 gene. Curr Genomics 15:203–216
Dutertre M, Sanchez G, Barbier J et al (2011) The emerging role of pre-messenger RNA splicing in stress responses: sending alternative messages and silent messengers. RNA Biol 8:740–747
Ghigna C, Valacca C, Biamonti G. (2008) Alternative splicing and tumor progression. Current genomics 9(8):556–70. PubMed PMID: 19516963; PubMed Central PMCID: PMC2694562
Wang L, Zuo B, Xu D, Ren Z, Zhang H, Li X, et al. (2012) Alternative splicing of the porcine glycogen synthase kinase 3beta (GSK-3beta) gene with differential expression patterns and regulatory functions. PLoS One. 7(7):e40250. PubMed PMID:22792253; PubMed Central PMCID:PMC3391277
Pal S, Gupta R, Davuluri RV (2012) Alternative transcription and alternative splicing in cancer. Pharmacol Ther 136:283–294
Shkreta L, Bell B, Revil T et al (2013) Cancer-associated perturbations in alternative pre-messenger RNA splicing. Cancer Treat Res 158:41–94
Prochazka L, Tesarik R, Turanek J (2014) Regulation of alternative splicing of CD44 in cancer. Cell Signal 26:2234–2239
Brown RL, Reinke LM, Damerow MS et al (2011) CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 121:1064–1074
Yoshida K, Ogawa S (2014) Splicing factor mutations and cancer. Wiley Interdiscip Rev RNA 5:445–459
Papaemmanuil E, Cazzola M, Boultwood J et al (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365:1384–1395
Yoshida K, Sanada M, Shiraishi Y et al (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64–69
Makishima H, Visconte V, Sakaguchi H et al (2012) Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 119:3203–3210
Bejar R (2014) Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica 99:956–964
Papaemmanuil E, Gerstung M, Malcovati L et al (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122:3616–3627
Haferlach T, Nagata Y, Grossmann V et al (2014) Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28:241–247
Bejar R, Stevenson K, Abdel-Wahab O et al (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496–2506
Quesada V, Conde L, Villamor N et al (2012) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44:47–52
Wang L, Lawrence MS, Wan Y et al (2011) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365:2497–2506
Bonnal S, Vigevani L, Valcarcel J (2012) The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 11:847–859
Matsunawa M, Yamamoto R, Sanada M et al (2014) Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia. Leukemia 28:1844–1850
Visconte V, Rogers HJ, Singh J et al (2012) SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 120:3173–3186
Visconte V, Tabarroki A, Zhang L et al (2014) Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. J Hematol Oncol 7:89
Dolatshad H, Pellagatti A, Fernandez-Mercado M et al (2015) Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia 29:1092–1103
Te Raa GD, Derks IA, Navrkalova V et al (2014) The impact of SF3B1 mutations in CLL on the DNA-damage response., Leukemia
Shiozawa Y, Sato-Otsubo S, Gallì A et al (2014) Comprehensive analysis of aberrant RNA splicing in myelodysplastic syndromes. Blood 124:826
Field MG, Harbour JW (2014) Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol 25:234–239
Malcovati L, Papaemmanuil E, Bowen DT et al (2011) Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 118:6239–6246
Baliakas P, Hadzidimitriou A, Sutton LA et al (2014) Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 29(2):329–336
Imielinski M, Berger AH, Hammerman PS et al (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107–1120
Bejar R, Stevenson KE, Caughey BA et al (2012) Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 30:3376–3382
Ilagan JO, Ramakrishnan A, Hayes B et al (2015) U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res 25:14–26
Shirai CL, Ley JN, White BS et al (2014) Mutant U2AF1 expression alters hematopoiesis and Pre-mRNA splicing in transgenic mice. Blood 124:827
Brooks AN, Choi PS, de Waal L et al (2014) A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One 9, e87361
Shao C, Yang B, Wu T et al (2014) Mechanisms for U2AF to define 3′ splice sites and regulate alternative splicing in the human genome. Nat Struct Mol Biol 21:997–1005
Moon H, Cho S, Loh TJ et al (2014) SRSF2 promotes splicing and transcription of exon 11 included isoform in Ron proto-oncogene. Biochim Biophys Acta 1839:1132–1140
Pandit S, Zhou Y, Shiue L et al (2013) Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing. Mol Cell 50:223–235
Mian SA, Smith AE, Kulasekararaj AG et al (2013) Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica 98:1058–1066
Patnaik MM, Lasho TL, Finke CM et al (2013) Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol 88:201–206
Meggendorfer M, Roller A, Haferlach T et al (2012) SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 120:3080–3088
Zhang J, Lieu YK, Ali AM et al (2015) Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci U S A 112:E4726–E4734
Kim E, Ilagan JO, Liang Y et al (2015) SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27:617–630
Kim E, Ilagan JO, Lee S et al (2014) SRSF2 mutations impair hematopoietic differentiation by altering exonic splicing enhancer preference. Blood 124:824
Neumann M, Vosberg S, Schlee C et al (2015) Mutational spectrum of adult T-ALL. Oncotarget 6:2754–2766
Kim SS, Stevenson KE, Yoda A et al (2013) Loss-of-function mutations in the splicing factor ZRSR2 Are common in Blastic plasmacytoid dendritic cell neoplasm and have male predominance. Blood 122:741
Madan V, Kanojia D, Li J et al (2015) Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun 6:6042
Kurtovic-Kozaric A, Przychodzen B, Singh J et al (2015) PRPF8 defects cause missplicing in myeloid malignancies. Leukemia 29:126–136
Dehm SM (2013) Test-firing ammunition for spliceosome inhibition in cancer. Clin Cancer Res 19:6064–6066
Eskens FA, Ramos FJ, Burger H et al (2013) Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res 19:6296–6304
Kashyap MK, Kumar D, Villa R et al (2015) Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. Haematologica 100:945–954
Hsu TY, Simon LM, Neill NJ et al (2015) The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525:384–388
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Bejar, R. (2016). Splicing Factor Mutations in Cancer. In: Yeo, G. (eds) RNA Processing. Advances in Experimental Medicine and Biology, vol 907. Springer, Cham. https://doi.org/10.1007/978-3-319-29073-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-29073-7_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-29071-3
Online ISBN: 978-3-319-29073-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)